All lobbying filings

Jeffrey J. Kimbell & Associates, Inc.

Jeffrey J. Kimbell & Associates, Inc. filed a Q1 termination report for Scpharmaceuticals, Inc. on April 20, 2026, reporting $12,500 in lobbying income.

Lobbying for Scpharmaceuticals, Inc. · pharmaceuticals

As filed: JEFFREY J. KIMBELL & ASSOCIATES, INC. for SCPHARMACEUTICALS, INC.

All filings by Jeffrey J. Kimbell & Associates, Inc. · Everything Scpharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q1 termination

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$12,500

What the client paid this registrant for the period.

Client based in

Massachusetts

Representation ended

Mar 31, 2026

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 5

KEITH STUDDARD

Previously held: Legislative Director, Rep. Marsha Blackburn
JOHN HERZOG

Previously held: Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President
JOHN R RAY

Previously held: Legislative Assistant, Rep. Mike Kelly
LAURA KEMPER

Previously held: Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services
BRETT MEEKS

Previously held: Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Medicare reimbursement of pharmaceuticals

Health Issues

general issues of interest to pharmaceutical companies

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.